title: [Massive bleeding symptoms in two patients with factor V inhibitor and antiphospholipid antibodies after treatment with ciprofloxacin].
abstract: BACKGROUND
  The development of factor V inhibitor is very rare, especially in combination with antiphospholipid antibodies.
  
  
  METHODS
  The paper describes the course of two patients with factor V inhibitor, antiphospholipid antibodies and massive bleeding symptoms after treatment with ciprofloxacin. At that time, ciprofloxacin was the only new drug given. DIAGNOSIS AND CLINICAL COURSE: First changes of the coagulation system were detected 4 days after start of treatment. In one case, occurrence was transient, and normalization was observed after terminating ciprofloxacin treatment. The other case ended with massive muscular and visceral bleedings and cardiovascular failure. Factor V inhibitor and antiphospholipid antibodies could be demonstrated even after termination of ciprofloxacin therapy.
  
  
  CONCLUSIONS
  The association of treatment with ciprofloxacin and development of factor V inhibitor and antiphospholipid antibodies is probably diagnosed to rarely. These two cases emphasize the necessity of meticulous clarification of a prolonged activated partial thromboplastin time (aPTT) and a drop in prothrombin time (PT) during and after ciprofloxacin treatment.
authors.affiliation: Medizinische Klinik I, Hämostaseologie, Johann Wolfgang Goethe-Universität, Frankfurt/Main. miesbach@em.uni-frankfurt.de
authors.forename: Wolfgang
authors.initials: W
authors.lastname: Miesbach
authors.forename: Jochen
authors.initials: J
authors.lastname: Voigt
authors.forename: Dirk
authors.initials: D
authors.lastname: Peetz
authors.forename: Inge
authors.initials: I
authors.lastname: Scharrer
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000890:Anti-Infective Agents / Q000008:administration & dosage / Q000009:adverse effects*; D017152:Antibodies, Antiphospholipid; D001780:Blood Coagulation Tests; D002939:Ciprofloxacin / Q000008:administration & dosage / Q000009:adverse effects*; D005165:Factor V / Q000037:antagonists & inhibitors*; D006470:Hemorrhage / Q000139:chemically induced*; D006801:Humans; D008297:Male; D010314:Partial Thromboplastin Time; D013997:Time Factors
chemical_list: D000890:Anti-Infective Agents; D017152:Antibodies, Antiphospholipid; D002939:Ciprofloxacin; D005165:Factor V